

June 2, 2010

Dear Customer,

We would like to take this opportunity to thank you for your continued support of Lantheus Medical Imaging. Together, we have made a positive impact in maintaining patient access to critical medical isotopes.

Lantheus has been working hard with its supply partners to ensure the uninterrupted supply of Xe-133 to our customers during June and July of this year.

Following the conclusion of multiple productive meetings and negotiations with the FDA, we are excited to tell you that we have now received FDA approval to distribute Xe-133 produced from targets irradiated at the REZ reactor in the Czech Republic.


This week's supply of Xe-133 will ship from our facilities today on schedule according to our normal release, distribution and logistics solutions. Our work to date and our qualification of the REZ reactor also ensures our ability to supply our Customers with Xe-133 throughout the month of July and going forward.

The qualification of the REZ reactor for Xe-133 is another example of our commitment to our Customers and the medical imaging community and is a telling example of our leadership in the diversification of our hot products supply chain.

At Lantheus Medical Imaging we are working to develop a globally diversified and balanced supply chain for the sourcing of key medical isotopes. Through a winning diversification approach, encompassing both the reactors and processors of key medical isotopes, we are ensuring that the medical imaging community has access to the medical isotopes that it relies on today and in the future.

We will continue to provide additional information on our supply of medical isotopes, and we encourage you to sign up on our website at [www.lantheus.com](http://www.lantheus.com).

Sincerely,



Michael A. Wojtas  
Associate Director  
Traditional Products